The epidemiology of HIV population viral load in twelve sub-Saharan African countries.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 19 09 2022
accepted: 05 06 2023
medline: 28 6 2023
pubmed: 26 6 2023
entrez: 26 6 2023
Statut: epublish

Résumé

We examined the epidemiology and transmission potential of HIV population viral load (VL) in 12 sub-Saharan African countries. We analyzed data from Population-based HIV Impact Assessments (PHIAs), large national household-based surveys conducted between 2015 and 2019 in Cameroon, Cote d'Ivoire, Eswatini, Kenya, Lesotho, Malawi, Namibia, Rwanda, Tanzania, Uganda, Zambia, and Zimbabwe. Blood-based biomarkers included HIV serology, recency of HIV infection, and VL. We estimated the number of people living with HIV (PLHIV) with suppressed viral load (<1,000 HIV-1 RNA copies/mL) and with unsuppressed viral load (viremic), the prevalence of unsuppressed HIV (population viremia), sex-specific HIV transmission ratios (number female incident HIV-1 infections/number unsuppressed male PLHIV per 100 persons-years [PY] and vice versa) and examined correlations between a variety of VL metrics and incident HIV. Country sample sizes ranged from 10,016 (Eswatini) to 30,637 (Rwanda); estimates were weighted and restricted to participants 15 years and older. The proportion of female PLHIV with viral suppression was higher than that among males in all countries, however, the number of unsuppressed females outnumbered that of unsuppressed males in all countries due to higher overall female HIV prevalence, with ratios ranging from 1.08 to 2.10 (median: 1.43). The spatial distribution of HIV seroprevalence, viremia prevalence, and number of unsuppressed adults often differed substantially within the same countries. The 1% and 5% of PLHIV with the highest VL on average accounted for 34% and 66%, respectively, of countries' total VL. HIV transmission ratios varied widely across countries and were higher for male-to-female (range: 2.3-28.3/100 PY) than for female-to-male transmission (range: 1.5-10.6/100 PY). In all countries mean log10 VL among unsuppressed males was higher than that among females. Correlations between VL measures and incident HIV varied, were weaker for VL metrics among females compared to males and were strongest for the number of unsuppressed PLHIV per 100 HIV-negative adults (R2 = 0.92). Despite higher proportions of viral suppression, female unsuppressed PLHIV outnumbered males in all countries examined. Unsuppressed male PLHIV have consistently higher VL and a higher risk of transmitting HIV than females. Just 5% of PLHIV account for almost two-thirds of countries' total VL. Population-level VL metrics help monitor the epidemic and highlight key programmatic gaps in these African countries.

Sections du résumé

BACKGROUND
We examined the epidemiology and transmission potential of HIV population viral load (VL) in 12 sub-Saharan African countries.
METHODS
We analyzed data from Population-based HIV Impact Assessments (PHIAs), large national household-based surveys conducted between 2015 and 2019 in Cameroon, Cote d'Ivoire, Eswatini, Kenya, Lesotho, Malawi, Namibia, Rwanda, Tanzania, Uganda, Zambia, and Zimbabwe. Blood-based biomarkers included HIV serology, recency of HIV infection, and VL. We estimated the number of people living with HIV (PLHIV) with suppressed viral load (<1,000 HIV-1 RNA copies/mL) and with unsuppressed viral load (viremic), the prevalence of unsuppressed HIV (population viremia), sex-specific HIV transmission ratios (number female incident HIV-1 infections/number unsuppressed male PLHIV per 100 persons-years [PY] and vice versa) and examined correlations between a variety of VL metrics and incident HIV. Country sample sizes ranged from 10,016 (Eswatini) to 30,637 (Rwanda); estimates were weighted and restricted to participants 15 years and older.
RESULTS
The proportion of female PLHIV with viral suppression was higher than that among males in all countries, however, the number of unsuppressed females outnumbered that of unsuppressed males in all countries due to higher overall female HIV prevalence, with ratios ranging from 1.08 to 2.10 (median: 1.43). The spatial distribution of HIV seroprevalence, viremia prevalence, and number of unsuppressed adults often differed substantially within the same countries. The 1% and 5% of PLHIV with the highest VL on average accounted for 34% and 66%, respectively, of countries' total VL. HIV transmission ratios varied widely across countries and were higher for male-to-female (range: 2.3-28.3/100 PY) than for female-to-male transmission (range: 1.5-10.6/100 PY). In all countries mean log10 VL among unsuppressed males was higher than that among females. Correlations between VL measures and incident HIV varied, were weaker for VL metrics among females compared to males and were strongest for the number of unsuppressed PLHIV per 100 HIV-negative adults (R2 = 0.92).
CONCLUSIONS
Despite higher proportions of viral suppression, female unsuppressed PLHIV outnumbered males in all countries examined. Unsuppressed male PLHIV have consistently higher VL and a higher risk of transmitting HIV than females. Just 5% of PLHIV account for almost two-thirds of countries' total VL. Population-level VL metrics help monitor the epidemic and highlight key programmatic gaps in these African countries.

Identifiants

pubmed: 37363921
doi: 10.1371/journal.pone.0275560
pii: PONE-D-22-26006
pmc: PMC10292693
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0275560

Subventions

Organisme : PEPFAR
Pays : United States
Organisme : CGH CDC HHS
ID : U2G GH001226
Pays : United States
Organisme : CGH CDC HHS
ID : U2G GH001271
Pays : United States

Informations de copyright

Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

PLoS One. 2012;7(3):e33328
pubmed: 22479384
AIDS. 2005 Nov 18;19(17):2001-7
pubmed: 16260907
N Engl J Med. 2018 May 17;378(20):1859-1861
pubmed: 29768142
J Acquir Immune Defic Syndr. 2021 Aug 1;87(Suppl 1):S17-S27
pubmed: 34166309
Lancet Infect Dis. 2013 May;13(5):459-64
pubmed: 23537801
Sci Transl Med. 2017 Dec 13;9(420):
pubmed: 29237762
J Acquir Immune Defic Syndr. 2021 Aug 1;87(Suppl 1):S6-S16
pubmed: 34166308
Sci Rep. 2016 Nov 02;6:36121
pubmed: 27805053
J Infect Dis. 2004 Apr 1;189(7):1209-15
pubmed: 15031789
AIDS. 2017 Jun 19;31(10):1461-1470
pubmed: 28426534
PLoS One. 2010 Jun 10;5(6):e11068
pubmed: 20548786
AIDS. 2012 Jan 28;26(3):345-53
pubmed: 22008660
J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):594-8
pubmed: 25585299
Lancet. 2010 Aug 14;376(9740):532-9
pubmed: 20638713
AIDS. 2014 Nov;28 Suppl 4:S469-76
pubmed: 25406750
N Engl J Med. 2016 Sep 1;375(9):830-9
pubmed: 27424812
J Acquir Immune Defic Syndr. 2019 Oct 1;82(2):e37-e39
pubmed: 31180996
J Int AIDS Soc. 2020 Feb;23(2):e25455
pubmed: 32091179
Curr Opin HIV AIDS. 2011 May;6(3):163-8
pubmed: 21502920
Med Decis Making. 2017 Feb;37(2):224-233
pubmed: 27646567
J Int AIDS Soc. 2017 Nov;20 Suppl 7:
pubmed: 29171193
J Acquir Immune Defic Syndr. 2021 Aug 1;87(Suppl 1):S73-S80
pubmed: 34166315
Trop Med Int Health. 2021 Dec;26(12):1609-1615
pubmed: 34637172
MMWR Morb Mortal Wkly Rep. 2018 Mar 22;68(11):267-272
pubmed: 30897075
N Engl J Med. 2000 Mar 30;342(13):921-9
pubmed: 10738050
AIDS. 2017 Jan 14;31(2):309-310
pubmed: 27831945
AIDS Res Ther. 2013 Dec 13;10(1):30
pubmed: 24330537
Lancet HIV. 2016 Apr;3(4):e183-90
pubmed: 27036994

Auteurs

Wolfgang Hladik (W)

Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.

Paul Stupp (P)

Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.

Stephen D McCracken (SD)

Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.

Jessica Justman (J)

ICAP at Columbia University, New York, New York, United States of America.

Clement Ndongmo (C)

Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.

Judith Shang (J)

Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.

Emily K Dokubo (EK)

Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.

Elizabeth Gummerson (E)

ICAP at Columbia University, New York, New York, United States of America.

Isabelle Koui (I)

Ministry of Health, Abidjan, Cote d'Ivoire.

Stephane Bodika (S)

Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.

Roger Lobognon (R)

Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.

Hermann Brou (H)

ICAP at Columbia University, New York, New York, United States of America.

Caroline Ryan (C)

Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.

Kristin Brown (K)

Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.

Harriet Nuwagaba-Biribonwoha (H)

ICAP at Columbia University, New York, New York, United States of America.

Leonard Kingwara (L)

National AIDS and STI's Control Programme, Ministry of Health, Nairobi, Kenya.

Peter Young (P)

Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.

Megan Bronson (M)

Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.

Duncan Chege (D)

ICAP at Columbia University, New York, New York, United States of America.

Optatus Malewo (O)

Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.

Yohannes Mengistu (Y)

Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.

Frederix Koen (F)

ICAP at Columbia University, New York, New York, United States of America.

Andreas Jahn (A)

Ministry of Health, Lilongwe, Malawi.

Andrew Auld (A)

Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.

Sasi Jonnalagadda (S)

Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.

Elizabeth Radin (E)

ICAP at Columbia University, New York, New York, United States of America.

Ndapewa Hamunime (N)

Ministry of Health, Windhoek, Namibia.

Daniel B Williams (DB)

Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.

Eugenie Kayirangwa (E)

Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.

Veronicah Mugisha (V)

ICAP at Columbia University, New York, New York, United States of America.

Rennatus Mdodo (R)

Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.

Stephen Delgado (S)

ICAP at Columbia University, New York, New York, United States of America.

Wilford Kirungi (W)

Ministry of Health, Kampala, Uganda.

Lisa Nelson (L)

Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.

Christine West (C)

Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.

Samuel Biraro (S)

ICAP at Columbia University, New York, New York, United States of America.

Kumbutso Dzekedzeke (K)

ICAP at Columbia University, New York, New York, United States of America.

Danielle Barradas (D)

Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.

Owen Mugurungi (O)

Ministry of Health and Child Care, Harare, Zimbabwe.

Shirish Balachandra (S)

Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.

Peter H Kilmarx (PH)

Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.

Godfrey Musuka (G)

ICAP at Columbia University, New York, New York, United States of America.

Hetal Patel (H)

Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.

Bharat Parekh (B)

Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.

Katrina Sleeman (K)

Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.

Robert A Domaoal (RA)

Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.

George Rutherford (G)

University of California San Francisco, San Francisco, California, United States of America.

Tsietso Motsoane (T)

Ministry of Health, Maseru, Lesotho.

Anne-Cécile Zoung-Kanyi Bissek (AZ)

Division of Operational Research for Health, Ministry of Health, Yaoundé, Cameroon.
Faculty of Medicine and Biomedical Sciences, University of Yaoundé, Yaoundé, Cameroon.

Mansoor Farahani (M)

ICAP at Columbia University, New York, New York, United States of America.

Andrew C Voetsch (AC)

Division of Global HIV and TB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH